메뉴 건너뛰기




Volumn 30, Issue 2, 2007, Pages 155-160

Lipid-altering therapies and the progression of atherosclerotic disease

Author keywords

Atherosclerosis; Cholesterol; HDL cholesterol; Interventional radiology; Intima media thickness; Intravascular ultrasound; LDL cholesterol; Peripheral vascular disease; Statin; Stroke

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; ATORVASTATIN; BEZAFIBRATE; BILE ACID SEQUESTRANT; CALCIUM CHANNEL BLOCKING AGENT; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC AGENT; PRAVASTATIN; SIMVASTATIN; TORCETRAPIB;

EID: 33846446076     PISSN: 01741551     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00270-006-0183-8     Document Type: Review
Times cited : (11)

References (67)
  • 1
    • 4444382796 scopus 로고    scopus 로고
    • Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study
    • Yusuf S, Hawken S, Ounpuu S, et al. (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 364(9438):937-952
    • (2004) Lancet , vol.364 , Issue.9438 , pp. 937-952
    • Yusuf, S.1    Hawken, S.2    Ounpuu, S.3
  • 2
    • 2942519743 scopus 로고    scopus 로고
    • Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study)
    • Rothwell PM, Coull AJ, Giles MF, et al. (2004) Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 363(9425):1925-1933
    • (2004) Lancet , vol.363 , Issue.9425 , pp. 1925-1933
    • Rothwell, P.M.1    Coull, A.J.2    Giles, M.F.3
  • 3
    • 0027380992 scopus 로고
    • Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials
    • Atkins D, Psaty BM, Koepsell TD, et al. (1993) Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials. Ann Intern Med 119(2):136-145
    • (1993) Ann Intern Med , vol.119 , Issue.2 , pp. 136-145
    • Atkins, D.1    Psaty, B.M.2    Koepsell, T.D.3
  • 4
    • 0023276691 scopus 로고
    • Compensatory enlargement of human atherosclerotic coronary arteries
    • Glagov S, Weisenberg E, Zarins CK, et al. (1987) Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 316(22):1371-1375
    • (1987) N Engl J Med , vol.316 , Issue.22 , pp. 1371-1375
    • Glagov, S.1    Weisenberg, E.2    Zarins, C.K.3
  • 5
    • 0031647047 scopus 로고    scopus 로고
    • Coronary artery remodelling and the assessment of stenosis by pathologists
    • Davies MJ (1998) Coronary artery remodelling and the assessment of stenosis by pathologists. Histopathology 33(6):497-500
    • (1998) Histopathology , vol.33 , Issue.6 , pp. 497-500
    • Davies, M.J.1
  • 6
    • 0029090411 scopus 로고
    • Coronary plaque disruption
    • Falk E, Shah PK, Fuster V (1995) Coronary plaque disruption. Circulation 92(3):657-671
    • (1995) Circulation , vol.92 , Issue.3 , pp. 657-671
    • Falk, E.1    Shah, P.K.2    Fuster, V.3
  • 7
    • 27544472697 scopus 로고    scopus 로고
    • Carotid intimalmedia thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors
    • Espeland MA, O'Leary DH, Terry JG, et al. (2005) Carotid intimalmedia thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med 6(1):3
    • (2005) Curr Control Trials Cardiovasc Med , vol.6 , Issue.1 , pp. 3
    • Espeland, M.A.1    O'Leary, D.H.2    Terry, J.G.3
  • 8
    • 0037148894 scopus 로고    scopus 로고
    • Ultrasound measurement of carotid plaque as a surrogate outcome for coronary artery disease
    • Spence JD (2002) Ultrasound measurement of carotid plaque as a surrogate outcome for coronary artery disease. Am J Cardiol 89(4A):10B-15B
    • (2002) Am J Cardiol 89(4A)
    • Spence, J.D.1
  • 9
    • 0037148917 scopus 로고    scopus 로고
    • Application of intravascular ultrasound to characterize coronary artery disease and assess the progression or regression of atherosclerosis
    • Nissen SE (2002) Application of intravascular ultrasound to characterize coronary artery disease and assess the progression or regression of atherosclerosis. Am J Cardiol 89(4A):24B-31B
    • (2002) Am J Cardiol 89(4A)
    • Nissen, S.E.1
  • 10
    • 0029598777 scopus 로고
    • Acute coronary thrombosis: The role of plaque disruption and its initiation and prevention
    • Davies MJ (1995) Acute coronary thrombosis: The role of plaque disruption and its initiation and prevention. Eur Heart J 16( Suppl L):3-7
    • (1995) Eur Heart J , vol.16 , Issue.SUPPL. L , pp. 3-7
    • Davies, M.J.1
  • 11
    • 0021164827 scopus 로고
    • The seven countries study: 2,289 deaths in 15 years
    • Keys A, Menotti A, Aravanis C, et al. (1984) The seven countries study: 2,289 deaths in 15 years. Prev Med 13(2):141-154
    • (1984) Prev Med , vol.13 , Issue.2 , pp. 141-154
    • Keys, A.1    Menotti, A.2    Aravanis, C.3
  • 12
    • 84911661493 scopus 로고
    • Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group
    • Buchwald H, Matts JP, Fitch LL, et al. (1992) Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group. JAMA 1268(11):1429-1433
    • (1992) JAMA , vol.1268 , Issue.11 , pp. 1429-1433
    • Buchwald, H.1    Matts, J.P.2    Fitch, L.L.3
  • 13
    • 0026582213 scopus 로고
    • Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)
    • Watts GF, Lewis B, Brunt JN, et al. (1992) Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 339(8793):563-569
    • (1992) Lancet , vol.339 , Issue.8793 , pp. 563-569
    • Watts, G.F.1    Lewis, B.2    Brunt, J.N.3
  • 14
    • 0032926503 scopus 로고    scopus 로고
    • Reduction of stroke incidence after myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) study. The Care Investigators
    • Plehn JF, Davis BR, Sacks FM, et al. (1999) Reduction of stroke incidence after myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 99(2):216-223
    • (1999) Circulation , vol.99 , Issue.2 , pp. 216-223
    • Plehn, J.F.1    Davis, B.R.2    Sacks, F.M.3
  • 15
    • 0035936503 scopus 로고    scopus 로고
    • Reduction of stroke events with pravastatin: The Prospective Pravastatin Pooling (PPP) Project
    • Byington RP, Davis BR, Plehn JF, et al. (2001) Reduction of stroke events with pravastatin: The Prospective Pravastatin Pooling (PPP) Project. Circulation 103(3):387-392
    • (2001) Circulation , vol.103 , Issue.3 , pp. 387-392
    • Byington, R.P.1    Davis, B.R.2    Plehn, J.F.3
  • 16
    • 0028845911 scopus 로고
    • Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program
    • Byington RP, Jukema JW, Salonen JT, et al. (1995) Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 92(9):2419-2425
    • (1995) Circulation , vol.92 , Issue.9 , pp. 2419-2425
    • Byington, R.P.1    Jukema, J.W.2    Salonen, J.T.3
  • 17
    • 0036023515 scopus 로고    scopus 로고
    • Treatment with Atorvastatin to the National Cholesterol Educational Program Goals versus Usual Care in Secondary Coronary Heart Disease Prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study
    • Athyros VG, Papageorgiou AA, Mercouris BR, et al. (2002) Treatment with Atorvastatin to the National Cholesterol Educational Program Goals versus Usual Care in Secondary Coronary Heart Disease Prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 18(4): 220-228
    • (2002) Curr Med Res Opin , vol.18 , Issue.4 , pp. 220-228
    • Athyros, V.G.1    Papageorgiou, A.A.2    Mercouris, B.R.3
  • 18
    • 0032966298 scopus 로고    scopus 로고
    • Systematic review on the risk and benefit of different cholesterol-lowering interventions
    • Bucher HC, Griffith LE, Guyatt GH (1999) Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 19(2):187-195
    • (1999) Arterioscler Thromb Vasc Biol , vol.19 , Issue.2 , pp. 187-195
    • Bucher, H.C.1    Griffith, L.E.2    Guyatt, G.H.3
  • 19
    • 26244432388 scopus 로고    scopus 로고
    • Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    • Baigent C, Keech A, Kearney PM, et al. (2005) Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267-1278
    • (2005) Lancet , vol.366 , Issue.9493 , pp. 1267-1278
    • Baigent, C.1    Keech, A.2    Kearney, P.M.3
  • 20
    • 21344475107 scopus 로고    scopus 로고
    • The changing face of cardiovascular risk
    • Grundy SM (2005) The changing face of cardiovascular risk. J Am Coll Cardiol 46(1):173-175
    • (2005) J Am Coll Cardiol , vol.46 , Issue.1 , pp. 173-175
    • Grundy, S.M.1
  • 21
    • 0029102150 scopus 로고
    • Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)
    • Byington RP, Furberg CD, Crouse JR, III, et al. (1995) Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II). Am J Cardiol 76(9):54C-59C
    • (1995) Am J Cardiol , vol.76 , Issue.9
    • Byington, R.P.1    Furberg, C.D.2    Crouse III, J.R.3
  • 22
    • 0029096765 scopus 로고
    • Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries
    • Salonen R, Nyyssonen K, Porkkala E, et al. (1995) Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 92(7):1758-1764
    • (1995) Circulation , vol.92 , Issue.7 , pp. 1758-1764
    • Salonen, R.1    Nyyssonen, K.2    Porkkala, E.3
  • 23
    • 10744225301 scopus 로고    scopus 로고
    • Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial
    • Nissen SE, Tuzcu EM, Schoenhagen P, et al. (2004) Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 291(9):1071-1080
    • (2004) JAMA , vol.291 , Issue.9 , pp. 1071-1080
    • Nissen, S.E.1    Tuzcu, E.M.2    Schoenhagen, P.3
  • 24
    • 33645524176 scopus 로고    scopus 로고
    • Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial
    • Nissen SE, Nicholls SJ, Sipahi I, et al. (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 295(13):1556-1565
    • (2006) JAMA , vol.295 , Issue.13 , pp. 1556-1565
    • Nissen, S.E.1    Nicholls, S.J.2    Sipahi, I.3
  • 25
    • 3042755369 scopus 로고    scopus 로고
    • Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: Subgroup analyses of the Scandinavian Simvastatin Survival Study (4S)
    • Pyorala K, Ballantyne CM, Gumbiner B, et al. (2004) Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: Subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 27(7):1735-1740
    • (2004) Diabetes Care , vol.27 , Issue.7 , pp. 1735-1740
    • Pyorala, K.1    Ballantyne, C.M.2    Gumbiner, B.3
  • 26
    • 1542345696 scopus 로고    scopus 로고
    • Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions
    • Collins R, Armitage J, Parish S, et al. (2004) Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363(9411):757-767
    • (2004) Lancet , vol.363 , Issue.9411 , pp. 757-767
    • Collins, R.1    Armitage, J.2    Parish, S.3
  • 27
    • 0344541709 scopus 로고    scopus 로고
    • Statin-sensitive dys-regulated AT1 receptor function and density in hypercholesterolemic men
    • Nickenig G, Baumer AT, Temur Y, et al. (1999) Statin-sensitive dys-regulated AT1 receptor function and density in hypercholesterolemic men. Circulation 100(21):2131-2134
    • (1999) Circulation , vol.100 , Issue.21 , pp. 2131-2134
    • Nickenig, G.1    Baumer, A.T.2    Temur, Y.3
  • 28
    • 5444258666 scopus 로고    scopus 로고
    • Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease
    • Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. (2004) Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 18(11):781-788
    • (2004) J Hum Hypertens , vol.18 , Issue.11 , pp. 781-788
    • Athyros, V.G.1    Mikhailidis, D.P.2    Papageorgiou, A.A.3
  • 29
    • 33846451669 scopus 로고    scopus 로고
    • Poulter N, Sever PS (2004) Do statins lower blood pressure? Evidence from the Anglo-Scandinavian Cardiac Outcomes Trial- Lipid-Lowering Arm (ASCOT-LLA). Circulation 110(Suppl III):III-402(abstract 1905)
    • Poulter N, Sever PS (2004) Do statins lower blood pressure? Evidence from the Anglo-Scandinavian Cardiac Outcomes Trial- Lipid-Lowering Arm (ASCOT-LLA). Circulation 110(Suppl III):III-402(abstract 1905)
  • 30
    • 0028813466 scopus 로고
    • Hyperlipidaemia, hypertension, and coronary heart disease
    • Goode GK, Miller JP, Heagerty AM (1995) Hyperlipidaemia, hypertension, and coronary heart disease. Lancet 345(8946):362-364
    • (1995) Lancet , vol.345 , Issue.8946 , pp. 362-364
    • Goode, G.K.1    Miller, J.P.2    Heagerty, A.M.3
  • 31
    • 0036867954 scopus 로고    scopus 로고
    • Lipid lowering: Another method of reducing blood pressure?
    • Wierzbicki AS (2002) Lipid lowering: Another method of reducing blood pressure? J Hum Hypertens 16(11):753-760
    • (2002) J Hum Hypertens , vol.16 , Issue.11 , pp. 753-760
    • Wierzbicki, A.S.1
  • 32
    • 33746218174 scopus 로고    scopus 로고
    • Statins and hypertension
    • Wierzbicki AS (2006) Statins and hypertension. J Hum Hypertens 20(8):551-553
    • (2006) J Hum Hypertens , vol.20 , Issue.8 , pp. 551-553
    • Wierzbicki, A.S.1
  • 33
    • 0028813466 scopus 로고
    • Hyperlipidaemia, hypertension, and coronary heart disease
    • Goode GK, Miller JP, Heagerty AM (1995) Hyperlipidaemia, hypertension, and coronary heart disease. Lancet 345:362-364
    • (1995) Lancet , vol.345 , pp. 362-364
    • Goode, G.K.1    Miller, J.P.2    Heagerty, A.M.3
  • 34
    • 33746257177 scopus 로고    scopus 로고
    • Effect of pravastatin on blood pressure in people with cardiovascular disease
    • Tonelli M, Sacks F, Pfeffer M, et al. (2006) Effect of pravastatin on blood pressure in people with cardiovascular disease. J Hum Hypertens 20(8):560-565
    • (2006) J Hum Hypertens , vol.20 , Issue.8 , pp. 560-565
    • Tonelli, M.1    Sacks, F.2    Pfeffer, M.3
  • 36
    • 0037164314 scopus 로고    scopus 로고
    • Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial
    • Shepherd J, Blauw GJ, Murphy MB, et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 360(9346):1623-1630
    • (2002) Lancet , vol.360 , Issue.9346 , pp. 1623-1630
    • Shepherd, J.1    Blauw, G.J.2    Murphy, M.B.3
  • 37
    • 0026582213 scopus 로고
    • Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)
    • Watts GF, Lewis B, Brunt JN, et al. (1992) Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 339(8793):563-569
    • (1992) Lancet , vol.339 , Issue.8793 , pp. 563-569
    • Watts, G.F.1    Lewis, B.2    Brunt, J.N.3
  • 38
    • 0035941990 scopus 로고    scopus 로고
    • Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study
    • Diabetes Atherosclerosis Intervention Study Group
    • Diabetes Atherosclerosis Intervention Study Group (2001) Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357(9260):905-910
    • (2001) Lancet , vol.357 , Issue.9260 , pp. 905-910
  • 39
    • 10044281651 scopus 로고    scopus 로고
    • Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extendedrelease niacin on atherosclerosis progression in secondary prevention patients treated with statins
    • Taylor AJ, Sullenberger LE, Lee HJ, et al. (2004) Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extendedrelease niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110(23):3512-3517
    • (2004) Circulation , vol.110 , Issue.23 , pp. 3512-3517
    • Taylor, A.J.1    Sullenberger, L.E.2    Lee, H.J.3
  • 40
    • 0036208934 scopus 로고    scopus 로고
    • Beyond LDL-C: The importance of raising HDL-C
    • Wierzbicki AS, Mikhailidis DP (2002) Beyond LDL-C: The importance of raising HDL-C. Curr Med Res Opin 18(1):36-44
    • (2002) Curr Med Res Opin , vol.18 , Issue.1 , pp. 36-44
    • Wierzbicki, A.S.1    Mikhailidis, D.P.2
  • 41
    • 4344665253 scopus 로고    scopus 로고
    • Raising highdensity lipoprotein cholesterol with reduction of cardiovascular risk: The role of nicotinic acid - A position paper developed by the European Consensus Panel on HDL-C
    • Chapman MJ, Assmann G, Fruchart JC, et al. (2004) Raising highdensity lipoprotein cholesterol with reduction of cardiovascular risk: The role of nicotinic acid - A position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 20(8):1253-1268
    • (2004) Curr Med Res Opin , vol.20 , Issue.8 , pp. 1253-1268
    • Chapman, M.J.1    Assmann, G.2    Fruchart, J.C.3
  • 43
    • 2942564118 scopus 로고    scopus 로고
    • The nicotinic acid receptor: A new mechanism for an old drug
    • Karpe F, Frayn KN (2004) The nicotinic acid receptor: A new mechanism for an old drug. Lancet 363(9424):1892-1894
    • (2004) Lancet , vol.363 , Issue.9424 , pp. 1892-1894
    • Karpe, F.1    Frayn, K.N.2
  • 44
    • 19944426989 scopus 로고    scopus 로고
    • A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: Effects on progression of coronary heart disease and clinical events
    • Whitney EJ, Krasuski RA, Personius BE, et al. (2005) A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: Effects on progression of coronary heart disease and clinical events. Ann Intern Med 142(2):95-104
    • (2005) Ann Intern Med , vol.142 , Issue.2 , pp. 95-104
    • Whitney, E.J.1    Krasuski, R.A.2    Personius, B.E.3
  • 45
    • 0023001772 scopus 로고
    • Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin
    • Canner PL, Berge KG, Wenger NK, et al. (1986) Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacin. J Am Coll Cardiol 8(6):1245-1255
    • (1986) J Am Coll Cardiol , vol.8 , Issue.6 , pp. 1245-1255
    • Canner, P.L.1    Berge, K.G.2    Wenger, N.K.3
  • 46
    • 0033527030 scopus 로고    scopus 로고
    • Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
    • Rubins HB, Robins SJ, Collins D, et al. (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 141(6):410-418
    • (1999) N Engl J Med , vol.141 , Issue.6 , pp. 410-418
    • Rubins, H.B.1    Robins, S.J.2    Collins, D.3
  • 47
    • 0023232216 scopus 로고
    • Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
    • Frick MH, Elo O, Haapa K, et al. (1987) Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317(20):1237-1245
    • (1987) N Engl J Med , vol.317 , Issue.20 , pp. 1237-1245
    • Frick, M.H.1    Elo, O.2    Haapa, K.3
  • 48
    • 0037099364 scopus 로고    scopus 로고
    • The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: Expert group recommendations
    • Sacks FM (2002) The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: Expert group recommendations. Am J Cardiol 90(2):139-143
    • (2002) Am J Cardiol , vol.90 , Issue.2 , pp. 139-143
    • Sacks, F.M.1
  • 49
    • 16344395132 scopus 로고    scopus 로고
    • Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?
    • Wierzbicki AS (2005) Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?. Curr Med Res Opin 21(2):299-306
    • (2005) Curr Med Res Opin , vol.21 , Issue.2 , pp. 299-306
    • Wierzbicki, A.S.1
  • 50
    • 0342506477 scopus 로고    scopus 로고
    • Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group
    • Frick MH, Syvanne M, Nieminen MS, et al. (1997) Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 96(7):2137-2143
    • (1997) Circulation , vol.96 , Issue.7 , pp. 2137-2143
    • Frick, M.H.1    Syvanne, M.2    Nieminen, M.S.3
  • 51
    • 0029982038 scopus 로고    scopus 로고
    • Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients
    • Ericsson CG, Hamsten A, Nilsson J, et al. (1996) Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347(9005):849-853
    • (1996) Lancet , vol.347 , Issue.9005 , pp. 849-853
    • Ericsson, C.G.1    Hamsten, A.2    Nilsson, J.3
  • 52
    • 28044452217 scopus 로고    scopus 로고
    • Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial
    • Keech A, Simes RJ, Barter P, et al. (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 366(9500):1849-1861
    • (2005) Lancet , vol.366 , Issue.9500 , pp. 1849-1861
    • Keech, A.1    Simes, R.J.2    Barter, P.3
  • 53
    • 33645086352 scopus 로고    scopus 로고
    • FIELDS of dreams, fields of tears: A perspective on the fibrate trials
    • Wierzbicki AS (2006) FIELDS of dreams, fields of tears: A perspective on the fibrate trials. Int J Clin Pract 60(4):442-449
    • (2006) Int J Clin Pract , vol.60 , Issue.4 , pp. 442-449
    • Wierzbicki, A.S.1
  • 54
    • 33746766313 scopus 로고    scopus 로고
    • Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease
    • Chapman MJ (2006) Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther 111(3):893-908
    • (2006) Pharmacol Ther , vol.111 , Issue.3 , pp. 893-908
    • Chapman, M.J.1
  • 55
    • 0242577955 scopus 로고    scopus 로고
    • Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial
    • Nissen SE, Tsunoda T, Tuzcu EM, et al. (2003) Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290(17):2292-2300
    • (2003) JAMA , vol.290 , Issue.17 , pp. 2292-2300
    • Nissen, S.E.1    Tsunoda, T.2    Tuzcu, E.M.3
  • 56
    • 7744243517 scopus 로고    scopus 로고
    • Lipid-altering agents: The future
    • Wierzbicki AS (2004) Lipid-altering agents: the future. Int J Clin Pract 58(11):1063-1072
    • (2004) Int J Clin Pract , vol.58 , Issue.11 , pp. 1063-1072
    • Wierzbicki, A.S.1
  • 57
    • 31644445200 scopus 로고    scopus 로고
    • Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease
    • Barter PJ, Kastelein JJ (2006) Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol 47(3):492-499
    • (2006) J Am Coll Cardiol , vol.47 , Issue.3 , pp. 492-499
    • Barter, P.J.1    Kastelein, J.J.2
  • 58
    • 26444544458 scopus 로고    scopus 로고
    • Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients
    • Kennedy J, Quan H, Buchan AM, et al. (2005) Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients. Stroke 36(10):2072-2076
    • (2005) Stroke , vol.36 , Issue.10 , pp. 2072-2076
    • Kennedy, J.1    Quan, H.2    Buchan, A.M.3
  • 59
    • 23744504398 scopus 로고    scopus 로고
    • Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study
    • Yokoi H, Nobuyoshi M, Mitsudo K, et al. (2005) Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study. Circ J 69(8):875-883
    • (2005) Circ J , vol.69 , Issue.8 , pp. 875-883
    • Yokoi, H.1    Nobuyoshi, M.2    Mitsudo, K.3
  • 60
    • 0031829175 scopus 로고    scopus 로고
    • The lipoprotein and coronary atherosclerosis study (LCAS): Lipid and metabolic factors related to atheroma and clinical events
    • Herd JA (1998) The lipoprotein and coronary atherosclerosis study (LCAS): Lipid and metabolic factors related to atheroma and clinical events. Am J Med 104(6A):42S-49S
    • (1998) Am J Med 104(6A)
    • Herd, J.A.1
  • 61
    • 0027981582 scopus 로고
    • Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS)
    • Multicenter Anti-Atheroma Study Investigators
    • Multicenter Anti-Atheroma Study Investigators (1994) Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 344(8923):633-638
    • (1994) Lancet , vol.344 , Issue.8923 , pp. 633-638
  • 62
    • 0027488722 scopus 로고
    • Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS)
    • Blankenhorn DH, Azen SP, Kramsch DM, et al. (1993) Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1119(10):969-976
    • (1993) Ann Intern Med , vol.1119 , Issue.10 , pp. 969-976
    • Blankenhorn, D.H.1    Azen, S.P.2    Kramsch, D.M.3
  • 63
    • 0028849703 scopus 로고
    • Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events. PLAC I investigation
    • Pitt B, Mancini GB, Ellis SG, et al. (1995) Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol 26(5):1133-1139
    • (1995) J Am Coll Cardiol , vol.26 , Issue.5 , pp. 1133-1139
    • Pitt, B.1    Mancini, G.B.2    Ellis, S.G.3
  • 64
    • 0029050796 scopus 로고
    • Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)
    • Jukema JW, Bruschke AV, van Boven AJ, et al. (1995) Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91(10):2528-2540
    • (1995) Circulation , vol.91 , Issue.10 , pp. 2528-2540
    • Jukema, J.W.1    Bruschke, A.V.2    van Boven, A.J.3
  • 65
    • 7744231805 scopus 로고    scopus 로고
    • Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: A randomized controlled trial
    • Nissen SE, Tuzcu EM, Libby P, et al. (2004) Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: A randomized controlled trial. JAMA 292(18):2217-2225
    • (2004) JAMA , vol.292 , Issue.18 , pp. 2217-2225
    • Nissen, S.E.1    Tuzcu, E.M.2    Libby, P.3
  • 66
    • 33645097996 scopus 로고    scopus 로고
    • Effect of ACAT inhibition on the progression of coronary atherosclerosis
    • Nissen SE, Tuzcu EM, Brewer HB, et al. (2006) Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med 354(12):1253-1263
    • (2006) N Engl J Med , vol.354 , Issue.12 , pp. 1253-1263
    • Nissen, S.E.1    Tuzcu, E.M.2    Brewer, H.B.3
  • 67
    • 20844449696 scopus 로고    scopus 로고
    • Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions
    • Tardif JC, Gregoire J, L'Allier PL, et al. (2004) Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation 110(21):3372-3377
    • (2004) Circulation , vol.110 , Issue.21 , pp. 3372-3377
    • Tardif, J.C.1    Gregoire, J.2    L'Allier, P.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.